Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Large Cell Neuroendocrine Carcinoma of the Lung: early-phase trial registry
4 of 5 indexed Large Cell Neuroendocrine Carcinoma of the Lung trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Large Cell Neuroendocrine Carcinoma of the Lung: 5 US clinical trials tracked, 4 recruiting.
Large Cell Neuroendocrine Carcinoma of the Lung is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Abdera Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition large-cell-neuroendocrine-carcinoma-of-the-lung
OPEN 4 | RECR 80% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)
Large Cell Neuroendocrine Carcinoma of the Lung lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Large Cell Neuroendocrine Carcinoma of the Lung on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Large Cell Neuroendocrine Carcinoma of the Lung is recruiting above its size-band peers.
4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Large Cell Neuroendocrine Carcinoma of the Lung research.
Abdera Therapeutics accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Large Cell Neuroendocrine Carcinoma of the Lung trials plan to enrol fewer than 100 people.
Median target enrolment is 41 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Large Cell Neuroendocrine Carcinoma of the Lung research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Novartis Pharmaceuticals
NCT07006727
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
Abdera Therapeutics
NCT06736418
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Legend Biotech USA
NCT05680922
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT06814496
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Case Comprehensive Cancer Center
NCT04010357
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Large Cell Neuroendocrine Carcinoma of the Lung records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Large Cell Neuroendocrine Carcinoma of the Lung trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Large Cell Neuroendocrine Carcinoma of the Lung page
5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Large Cell Neuroendocrine Carcinoma of the Lung trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Abdera Therapeutics sponsors the most Large Cell Neuroendocrine Carcinoma of the Lung trials on record, review their full trial history before evaluating a specific study. See Abdera Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Large Cell Neuroendocrine Carcinoma of the Lung condition card totals 5 registered trials; most-linked intervention Abemaciclib,; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.